Effects of STI571 on acute myelogenous leukemia (AML) cells in vitro.

被引：0
|
作者：
Scappini, B [1 ]
Onida, F [1 ]
Kantarjian, H [1 ]
Li, D [1 ]
Keating, MJ [1 ]
Beran, M [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
492
引用
收藏
页码：114A / 115A
页数：2
相关论文
共 50 条
  • [21] Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia
    Gorre, ME
    Sawyers, CL
    CURRENT OPINION IN HEMATOLOGY, 2002, 9 (04) : 303 - 307
  • [22] Minimal residual disease (MRD) monitoring in chronic myelogenous leukemia (CML) patients treated with STI571 (Glivec®)
    Roche-Lestienne, C
    Grardel-Duflos, N
    Cornu-Soenen, V
    Laï, JL
    Roumier, C
    Berthaud, P
    Cosson, A
    Facon, T
    Preudhomme, C
    LEUKEMIA, 2001, 15 (12) : 2023 - 2023
  • [23] STI571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy
    Michael J. Mauro
    Michael E. O'Dwyer
    Brian J. Druker
    Cancer Chemotherapy and Pharmacology, 2001, 48 : S77 - S78
  • [24] Imatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatment
    Cowan-Jacob, SW
    Guez, V
    Fendrich, G
    Griffin, JD
    Fabbro, D
    Furet, P
    Liebetanz, J
    Mestan, J
    Manley, PW
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2004, 4 (03) : 285 - 299
  • [25] Pharmacogenetic analysis of cytogenetic response in chronic myelogenous leukemia patients treated with imatinib (Glivec®/Gleevec™, STI571).
    Malinowski, RH
    Dressman, M
    McLean, LA
    Gathmann, I
    Capdeville, R
    BLOOD, 2002, 100 (11) : 547A - 547A
  • [26] Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells
    Kawaguchi, Y
    Jinnai, I
    Nagai, K
    Yagasaki, F
    Yakata, Y
    Matsuo, T
    Kuriyama, K
    Tomonaga, M
    LEUKEMIA, 2001, 15 (04) : 590 - 594
  • [27] Immunomodulatory effects of STI571 in chronic myeloid leukaemia
    Bund, D.
    Yang, T.
    Buhmann, R.
    Kolb, H. -J.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S317 - S317
  • [28] Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells
    Y Kawaguchi
    I Jinnai
    K Nagai
    F Yagasaki
    Y Yakata
    T Matsuo
    K Kuriyama
    M Tomonaga
    Leukemia, 2001, 15 : 590 - 594
  • [29] Phosphorylation of Bcr-Abl kinase and its downstream substrates in response to STI571 treatment in human chronic myelogenous leukemia cells
    不详
    MOLECULAR & CELLULAR PROTEOMICS, 2005, 4 (08) : S465 - S465
  • [30] Effects of STI571 on radioimmunotherapy of colorectal cancer.
    Baranowska-Kortylewicz, J
    Abe, M
    Kurizaki, T
    Pietras, K
    Ostman, A
    Kortylewicz, ZP
    Enke, CA
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6189S - 6189S
12345